ABVC BIOPHARMA, INC.

Nasdaq:ABVC

Pharmaceutical Preparations·FREMONT, CA

CEO

Crockett Robert G

CFO

Stolz Kevin Patrick

Summary Financials

Revenue

$509,589

+234.3% YoY

FY 2025

Adj. EBITDA

-$4.7M

-921.0% margin

FY 2025

Net Income

-$4.9M

-962.1% margin

FY 2025

EPS (Diluted)

-$0.42

FY 2025

Stock Price

$1.42

-3.4%

2026-03-11

52W Range

$0.61 – $5.48

P/E Ratio

-3.4x

Market Cap

$36.1M

Cash

$248,382

FY 2025

Total Debt

$840,252

FY 2025

Net Debt

$591,870

FY 2025

Enterprise Value

$36.7M

Debt / EBITDA

-0.1x

FY 2025

EV / EBITDA

-7.8x

Employees

—

Revenue

$509,589

+234.3% YoY

FY 2025

Adj. EBITDA

-$4.7M

-921.0% margin

FY 2025

Net Income

-$4.9M

-962.1% margin

FY 2025

EPS (Diluted)

-$0.42

FY 2025

Stock Price

$1.42

-3.4%

2026-03-11

52W Range

$0.61 – $5.48

P/E Ratio

-3.4x

Market Cap

$36.1M

Cash

$248,382

FY 2025

Total Debt

$840,252

FY 2025

Net Debt

$591,870

FY 2025

Enterprise Value

$36.7M

Debt / EBITDA

-0.1x

FY 2025

EV / EBITDA

-7.8x

Employees

—